Russell Frank Company’s Heron Therapeutics HRTX Stock Holding History

Russell Frank Company’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$475K	Sell	25,002 -23,828	-49%	-$470K	﹤0.01%	2468
2015 Q4	$1.37M	Buy	48,830 +15,585	+47%	+$417K	﹤0.01%	2059
2015 Q3	$811K	Sell	33,245 -639	-2%	-$21.3K	﹤0.01%	2291
2015 Q2	$1.06M	Sell	33,884 -23,570	-41%	-$443K	﹤0.01%	2285
2015 Q1	$836K	Buy	+57,454	New	+$648K	﹤0.01%	2227

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Frank Company's HRTX Position: Q1 2016 in Review

Russell Frank Company reduced its Heron Therapeutics (HRTX) stake by 49% in Q1 2016, selling an estimated $470K and leaving 25,002 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

Russell Frank Company first reported a position in HRTX in Q1 2015 and has held it in 5 quarters since. The position peaked at $1.37M in Q4 2015. 99 funds tracked by Wall St. Rank hold HRTX as of Q1 2016.

Russell Frank Company held 25,002 shares of Heron Therapeutics worth $475K as of Q1 2016.
Russell Frank Company sold 23,828 Heron Therapeutics shares in Q1 2016, an estimated $470K.
Heron Therapeutics made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2468 holding.
Russell Frank Company first reported a position in Heron Therapeutics in Q1 2015 and has held it in 5 quarters since.
Russell Frank Company's Heron Therapeutics position peaked at $1.37M in Q4 2015.
99 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.